DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features

  • Mateos, Maria Victoria
  • Robak, Pawel
  • Hus, Marek
  • Fu, Chengcheng
  • Zherebtsova, Vera
  • ... Kim, Kihyun
  • 외 13명
Citations

WEB OF SCIENCE

0

키워드

MMmultiple myelomaantibody-drug conjugatebelantamab mafodotinDREAMM-7
제목
DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features
저자
Mateos, Maria VictoriaRobak, PawelHus, MarekFu, ChengchengZherebtsova, VeraWard, ChristopherHo, P. JoyHajek, RomanKim, KihyunDimopoulos, MeletiosCerchione, ClaudioPirooz, NickMcKeown, AstridLin, Chee PaulBaig, HenaEccersley, LydiaRoy-Ghanta, SumitaOpa, JoannaHungria, Vania
발행일
2025-09
유형
Meeting Abstract
저널명
Clinical Lymphoma, Myeloma and Leukemia
25